Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on Chemocentryx Inc. on Tuesday, setting a price target of $75, which is approximately 28.45% above the present share price of $58.39.
Gilson expects Chemocentryx Inc. to post earnings per share (EPS) of -$0.35 for the second quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in ChemoCentryx (NASDAQ:CCXI), with an average price target of $72.57.
The analysts price targets range from a high of $95 to a low of $64.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $5.86 million and a net profit of -$22.12 million. The company's market cap is $3.99 billion.
According to TipRanks.com, Canaccord Genuity analyst Michelle Gilson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 31.7% and a 56.94% success rate.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.